Boston Scientific Corp
Close on Nov 18, 2026Market cap $63.24BP/E 17.7Yield –
Boston Scientific Adjusted EBITDA (Non-GAAP, $M) by Quarter
Adjusted EBITDA (Non-GAAP, $M) ($M)
Boston Scientific Adjusted EBITDA (Non-GAAP, $M): $1,464M in Q3 2026, down 2.5% from a year earlier.
Where the Q3 2026 figure comes from
“Adjusted EBITDA $ 1,558 $ 1,540 $ 1,630 $ 1,464 $ 6,192”
Source: BSX FY2026Q3 Financial & Operational Highlights Presentation ↗
Reported in Quarterly FOH Appendix C (Reconciliation of Debt to Adjusted EBITDA) & Form 10-K/10-Q Note F.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up adjusted EBITDA (Non-GAAP, $M)
- Trailing 12-Month (TTM) Adjusted EBITDA ($M)6,192 · Q3 2026
- GAAP EBITDA ($M)1,191 · Q3 2026
- Trailing 12-Month (TTM) GAAP EBITDA ($M)5,419 · Q3 2026
- Gross Total Debt (EBITDA Reconciliation Basis, $M)11,952 · Q3 2026
- Gross Debt to Adjusted EBITDA Leverage Ratio (x)1.90 · Q3 2026
- Revolving Credit Facility Consolidated Leverage Ratio — Actual (x)1.95 · Q3 2026
- Revolving Credit Facility Consolidated Leverage Ratio — Maximum Covenant Limit (x)3.75 · Q3 2026
Cite this data
StockData. (2026). Boston Scientific Adjusted EBITDA (Non-GAAP, $M) ($M), quarterly Q2 2022–Q3 2026 [Data set]. Compiled from Boston Scientific SEC filings and investor materials. https://stockdatahq.com/stocks/bsx/kpis/lev-adj-ebitda
See every metric in the Boston Scientific KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?